Synopsis
Synopsis
0
KDMF
0
FDF
0
FDA Orange Book
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. Antiminth
2. Combantrin
3. Embonate, Pyrantel
4. Embovin
5. Pamoate, Pyrantel
6. Pyrantel Embonate
1. 22204-24-6
2. Pyrantel Embonate
3. Antiminth
4. Combantrin
5. Pyrantel (pamoate)
6. Cp-10,423-16
7. Pyrantel (as Pamoate)
8. Embovin
9. (e)-1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)pyrimidine 4,4'-methylenebis(3-hydroxy-2-naphthoate) (1:1)
10. Nsc-355080
11. Chebi:8655
12. Cp 10423-16
13. 81bk194z5m
14. Nsc355080
15. (e)-1-methyl-2-(2-(thiophen-2-yl)vinyl)-1,4,5,6-tetrahydropyrimidine 4,4'-methylenebis(3-hydroxy-2-naphthoate)
16. Cp-10423-16
17. Cp-10423-18
18. Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)ethenyl)-, (e)-, Compd. With 4,4'-methylenebis(3-hydroxy-2-naphthalenecarboxylic Acid) (1:1)
19. Cobantril
20. Sentry Hc Worm X
21. 2-naphthalenecarboxylic Acid, 4,4'-methylenebis[3-hydroxy-, Compd. With 1,4,5,6-tetrahydro-1-methyl-2-[(1e)-2-(2-thienyl)ethenyl]pyrimidine (1:1)
22. 4-[(3-carboxy-2-hydroxy-1-naphthyl)methyl]-3-hydroxy-naphthalene-2-carboxylic Acid; 1-methyl-2-[(e)-2-(2-thienyl)vinyl]-5,6-dihydro-4h-pyrimidine
23. 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic Acid;1-methyl-2-[(e)-2-thiophen-2-ylethenyl]-5,6-dihydro-4h-pyrimidine
24. Sentry Hc Worm X Ds
25. Einecs 244-837-1
26. Vetscription Sure Shot 2x
27. Nsc 355080
28. Pyirantelpamoate
29. Unii-81bk194z5m
30. Pyrantel Pamoates
31. Pyranteli Embonas
32. Antiminth (tn)
33. Pyrantel Pamoate [usan:usp:jan]
34. 2-naphthalenecarboxylic Acid, 4,4'-methylenebis(3-hydroxy-, Compd. With 1,4,5,6-tetrahydro-1-methyl-2-((1e)-2-(2-thienyl)ethenyl)pyrimidine (1:1)
35. Spectrum5_001373
36. Pyrantel Pamoate, Bioxtra
37. (3-hydroxy-2-naphthoate)
38. Schembl41025
39. 2-naphthalenecarboxylic Acid, 4,4'-methylenebis(3-hydroxy-, Compd. With (e)-1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)ethenyl)pyrimidine (1:1)
40. Pyrantel Pamoate [mi]
41. Spectrum1500517
42. Pyrantel Pamoate [jan]
43. Pyrantel Pamoate (jp17/usp)
44. Schembl7793068
45. Pyrantel Pamoate [usan]
46. Chembl1599768
47. Pyrantel Pamoate [vandf]
48. Hms500m16
49. Pyrantel Pamoate Sigmaultra,(s)
50. Amy3564
51. Dtxsid40897057
52. Pyrantel Embonate [mart.]
53. Pyrantel Pamoate [usp-rs]
54. Hms1920n06
55. Hms2090j21
56. Hms2092e07
57. Pharmakon1600-01500517
58. Pyrantel Embonate [who-dd]
59. Pyrantel Embonate [who-ip]
60. Ccg-39242
61. Mfcd00072037
62. Nsc757303
63. S2501
64. Stl481883
65. Pyrantel Pamoate [green Book]
66. Akos015908224
67. Cs-3869
68. Nsc-757303
69. Idi1_000254
70. Pyrantel Embonate [ep Monograph]
71. Pyrantel Pamoate [usp Monograph]
72. Ncgc00094552-01
73. Ncgc00094552-02
74. Ncgc00094552-03
75. Pyranteli Embonas [who-ip Latin]
76. 2-naphthoic Acid, 4,4'-methylenebis(3-hydroxy-, Compd. With (e)-1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)pyrimidine (1:1)
77. 4,4'-methylenebis(3-hydroxy-2-naphthoic) Acid, Compound With (e)-1,4,5,6-tetrahydro-1-methyl-2-(2-(2-thienyl)vinyl)pyrimidine (1:1)
78. Ac-24204
79. As-12185
80. Bp166202
81. Hy-12640
82. Sbi-0051499.p003
83. C07389
84. D00486
85. F21340
86. 204p246
87. A816013
88. Sr-05000001708
89. Q3489331
90. Sr-05000001708-1
91. Pyrantel Pamoate, Vetranal(tm), Analytical Standard
92. (e)-1-methyl-2-(2-(thiophen-2-yl)vinyl)-1,4,5,6
93. Pyrantel Embonate, European Pharmacopoeia (ep) Reference Standard
94. Pyrantel Pamoate, United States Pharmacopeia (usp) Reference Standard
95. Pyrimidine,1,4,5,6-tetrahydro-1-methyl-2-[(1e)-2-(2-thienyl)ethenyl]-
96. (e)-1,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine 4,4'-methylenebis[3-hydroxy-2-naphthoate] (1:1)
97. 2-naphthalenecarboxylic Acid,4'-methylenebis[3-hydroxy-, Compd. With (e)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)ethenyl]pyrimidine (1:1)
98. 2-naphthoic Acid,4'-methylenebis[3-hydroxy-, Compd. With (e)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)
99. 4,4'-methanediylbis(3-hydroxynaphthalene-2-carboxylic Acid) - 1-methyl-2-[(e)-2-(thiophen-2-yl)ethenyl]-1,4,5,6-tetrahydropyrimidine (1:1)
100. 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic Acid,1-methyl-2-[(e)-2-thiophen-2-ylethenyl]-5,6-dihydro-4h-pyrimidine
101. Pyrimidine, 1,4,5,6-tetrahydro-1-methyl-2-[2-(-2-thienyl)ethenyl-, (e)-, With 4,4'-methylenebis[3-hydroxy-2-naphthalenecarboxylic Acid (1:1)
Molecular Weight | 594.7 g/mol |
---|---|
Molecular Formula | C34H30N2O6S |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 6 |
Exact Mass | 594.18245785 g/mol |
Monoisotopic Mass | 594.18245785 g/mol |
Topological Polar Surface Area | 159 Ų |
Heavy Atom Count | 43 |
Formal Charge | 0 |
Complexity | 816 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Antinematodal Agents
Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice. (See all compounds classified as Antinematodal Agents.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
NDC Package Code : 52932-0714
Start Marketing Date : 2009-09-29
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
VMF Number : 5562
Submission : 1996-05-23
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19815
Submission : 2006-09-29
Status : Active
Type : II
NDC Package Code : 52286-0019
Start Marketing Date : 2009-11-04
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23040
Submission : 2009-08-14
Status : Active
Type : II
NDC Package Code : 52286-0019
Start Marketing Date : 2009-11-04
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7822
Submission : 1988-12-15
Status : Active
Type : II
Certificate Number : R1-CEP 2005-294 - Rev 02
Issue Date : 2020-12-14
Type : Chemical
Substance Number : 1680
Status : Valid
Date of Issue : 2022-06-08
Valid Till : 2025-07-02
Written Confirmation Number : WC-0091
Address of the Firm :
NDC Package Code : 57451-0004
Start Marketing Date : 2012-04-12
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
VMF Number : 5428
Submission : 1992-08-28
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20613
Submission : 2007-06-15
Status : Active
Type : II
Certificate Number : R1-CEP 2006-162 - Rev 02
Issue Date : 2023-02-15
Type : Chemical
Substance Number : 1680
Status : Valid
Registration Number : 221MF10046
Registrant's Address : Sethna 4th floor 55 Maharshi karve road Marine Lines,Mumbai-400002,INDIA
Initial Date of Registration : 2009-02-25
Latest Date of Registration : --
Date of Issue : 2022-07-27
Valid Till : 2025-07-21
Written Confirmation Number : WC-0087-(Annexure-1)
Address of the Firm :
NDC Package Code : 22665-0002
Start Marketing Date : 2010-07-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Pyrantel Pamoate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pyrantel Pamoate, including repackagers and relabelers. The FDA regulates Pyrantel Pamoate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pyrantel Pamoate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pyrantel Pamoate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pyrantel Pamoate supplier is an individual or a company that provides Pyrantel Pamoate active pharmaceutical ingredient (API) or Pyrantel Pamoate finished formulations upon request. The Pyrantel Pamoate suppliers may include Pyrantel Pamoate API manufacturers, exporters, distributors and traders.
click here to find a list of Pyrantel Pamoate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Pyrantel Pamoate DMF (Drug Master File) is a document detailing the whole manufacturing process of Pyrantel Pamoate active pharmaceutical ingredient (API) in detail. Different forms of Pyrantel Pamoate DMFs exist exist since differing nations have different regulations, such as Pyrantel Pamoate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Pyrantel Pamoate DMF submitted to regulatory agencies in the US is known as a USDMF. Pyrantel Pamoate USDMF includes data on Pyrantel Pamoate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Pyrantel Pamoate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Pyrantel Pamoate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Pyrantel Pamoate Drug Master File in Japan (Pyrantel Pamoate JDMF) empowers Pyrantel Pamoate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Pyrantel Pamoate JDMF during the approval evaluation for pharmaceutical products. At the time of Pyrantel Pamoate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Pyrantel Pamoate suppliers with JDMF on PharmaCompass.
A Pyrantel Pamoate CEP of the European Pharmacopoeia monograph is often referred to as a Pyrantel Pamoate Certificate of Suitability (COS). The purpose of a Pyrantel Pamoate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Pyrantel Pamoate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Pyrantel Pamoate to their clients by showing that a Pyrantel Pamoate CEP has been issued for it. The manufacturer submits a Pyrantel Pamoate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Pyrantel Pamoate CEP holder for the record. Additionally, the data presented in the Pyrantel Pamoate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Pyrantel Pamoate DMF.
A Pyrantel Pamoate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Pyrantel Pamoate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Pyrantel Pamoate suppliers with CEP (COS) on PharmaCompass.
A Pyrantel Pamoate written confirmation (Pyrantel Pamoate WC) is an official document issued by a regulatory agency to a Pyrantel Pamoate manufacturer, verifying that the manufacturing facility of a Pyrantel Pamoate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Pyrantel Pamoate APIs or Pyrantel Pamoate finished pharmaceutical products to another nation, regulatory agencies frequently require a Pyrantel Pamoate WC (written confirmation) as part of the regulatory process.
click here to find a list of Pyrantel Pamoate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pyrantel Pamoate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pyrantel Pamoate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pyrantel Pamoate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pyrantel Pamoate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pyrantel Pamoate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pyrantel Pamoate suppliers with NDC on PharmaCompass.
Pyrantel Pamoate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pyrantel Pamoate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pyrantel Pamoate GMP manufacturer or Pyrantel Pamoate GMP API supplier for your needs.
A Pyrantel Pamoate CoA (Certificate of Analysis) is a formal document that attests to Pyrantel Pamoate's compliance with Pyrantel Pamoate specifications and serves as a tool for batch-level quality control.
Pyrantel Pamoate CoA mostly includes findings from lab analyses of a specific batch. For each Pyrantel Pamoate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pyrantel Pamoate may be tested according to a variety of international standards, such as European Pharmacopoeia (Pyrantel Pamoate EP), Pyrantel Pamoate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pyrantel Pamoate USP).
LOOKING FOR A SUPPLIER?